Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 11, 2017

TapImmune launches Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer

US-based immuno-oncology company TapImmune launches its Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer patients.

US-based immuno-oncology company TapImmune launches its Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer patients.

The TPIV 200 is a multi-epitope folate receptor peptide vaccine that fights breast and ovarian cancer.

The product is composed of five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF).

The Phase II ovarian cancer study will be conducted as a double-blind, placebo controlled study intended to evaluate the benefits of using TPIV 200 in combination with standard of care chemotherapy.

TapImmune president and COO Dr John Bonfiglio said: "The opening of this study represents the fulfillment of a major 2016 milestone.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

"We now have three clinical studies utilising TPIV 200 with approvals to enrol patients.

"The opening of this study represents the fulfillment of a major 2016 milestone."

“A fourth study in triple-negative breast cancer sponsored by the Mayo clinic with a $13.3m grant from the Department of Defence is scheduled to begin shortly.

“We believe the depth of these clinical programmes will give us an excellent understanding of how this exciting T-cell therapy can potentially be used in the treatment of both triple-negative breast and ovarian cancers."

According to the National Institute of Health, most patients with advanced ovarian cancer experience a recurrence of the disease within three years, with the initial recurrence generally being platinum-sensitive.

Platinum-sensitive recurrence describes the condition when the patient who experienced the relapse after chemotherapy can be administered with the same therapy to treat disease recurrence.


Image: TapImmune tests T-cell therapy to fight ovarian cancer. Photo: PRNewsFoto/TapImmune, Inc.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU